Addiction & Substance Use Disorder Statistics (Updated 2026)

Last reviewed: June 2026  ·  Sources: SAMHSA • CDC • NIDA  ·  Reading time: approx. 10 minutes

The statistics on addiction in America tell two stories at once: one of genuine progress, and one of unfinished business. For the first time in years, overdose deaths have fallen sharply. Yet nearly 50 million Americans still meet the clinical criteria for a substance use disorder, and the overwhelming majority of them never receive professional care. This resource compiles the most current data available—drawing on 2025–2026 reports from SAMHSA, CDC, and NIDA—to give clinicians, researchers, families, and people in recovery an accurate picture of where things stand.

1. Overall Substance Use Disorder Prevalence
2. Overdose Deaths & The Fentanyl Shift
3. The Treatment Gap
4. Alcohol Use Statistics
5. Opioids & Synthetic Opioids
6. Cannabis
7. Cocaine & Methamphetamine
8. Hallucinogens & Psychedelics
9. Nicotine & Youth Vaping
10. Demographics & Vulnerable Populations
11. Co-Occurring Mental Health Disorders
12. Treatment Outcomes & Recovery
13. References & Citations

Overall Substance Use Disorder Prevalence

Substance use disorders are among the most common—and most undertreated—health conditions in the United States. According to SAMHSA’s most recent National Survey on Drug Use and Health (NSDUH), the scale of the problem is immense:

These figures reflect a fourfold increase from 2002 prevalence estimates, driven in part by improved diagnostic criteria under the DSM-5, expanded survey methodology, and genuine rises in cannabis and opioid disorders. What hasn’t kept pace is the treatment system’s capacity to absorb those in need.

Overdose Deaths & The Fentanyl Shift

The most significant public health development in recent U.S. addiction data is a dramatic decline in overdose fatalities. After years of climbing, drug overdose deaths fell to 79,384 in the most recent reporting period—a drop of roughly 24.4% from the peak of over 105,000 deaths in prior years (CDC, 2026).

The decline is largely attributable to the reduced availability of highly potent illicitly manufactured fentanyl in some regions, expanded distribution of naloxone (Narcan), and growing uptake of medications for opioid use disorder (MOUD). Synthetic opioid-involved fatalities fell 35.6%, dropping from 22.2 to 14.3 deaths per 100,000 people (CDC, 2026).

The Treatment Gap

Perhaps the most persistent and troubling finding in addiction research is the vast distance between those who need treatment and those who receive it. SAMHSA’s 2025 data confirm this gap has not meaningfully closed despite decades of policy attention.

Among those who don’t seek help, the most commonly cited barriers are cost and lack of insurance coverage, not believing treatment is necessary, not being ready to stop using, and stigma. These barriers are not evenly distributed: low-income individuals, people in rural areas, and racial and ethnic minorities face compounding obstacles to accessing care.

Access to medication-assisted treatment (MAT)—particularly buprenorphine and methadone for opioid use disorder—remains limited in many parts of the country. Federal policy changes since 2023 have relaxed prescribing rules for buprenorphine, yet prescriber supply and pharmacy access have not followed in many communities.

Alcohol Use Statistics

Alcohol use disorder remains the most prevalent substance use disorder in the country, accounting for a substantial share of preventable deaths, hospitalizations, and lost productivity each year.

Demographic Variation in Heavy Alcohol Use

Race and ethnicity show measurable differences in patterns of heavy alcohol use, with direct implications for culturally tailored prevention and treatment:

Alcohol withdrawal can be medically serious—in some cases life-threatening—due to the risk of seizures and delirium tremens. This is why medically supervised detox is typically the recommended first step. Evidence-based medications including naltrexone, acamprosate, and disulfiram are most effective when combined with behavioral therapies like Cognitive Behavioral Therapy (CBT).

Opioids & Synthetic Opioids

The opioid crisis has reshaped American public health infrastructure over the past two decades. While the latest data offer genuine grounds for optimism on overdose fatality rates, opioid misuse remains a major clinical and social challenge.

Synthetic Opioid Fatality Decline

The 35.6% drop in synthetic opioid-involved overdose deaths—falling from 22.2 to 14.3 deaths per 100,000 people—is the most striking data point of 2026 (CDC, 2026). Even so, synthetic opioids remain the single deadliest category in the overdose landscape. The progress is meaningful; the work is far from complete.

Prescription Opioid Misuse Trends

Past-year misuse of prescription opioids has declined from 3.0% to 2.6% of the population (SAMHSA, 2025), reflecting in part more restrictive prescribing practices and updated CDC clinical guidelines. For individuals seeking help, treatment options include heroin addiction programs, fentanyl-specific treatment, and OxyContin/oxycodone treatment. Medication-assisted approaches using buprenorphine or methadone are recognized as the gold standard by both the World Health Organization and ASAM.

Cannabis Use & Cannabis Use Disorder

Cannabis legalization has accelerated across the United States since 2020, and use rates have tracked upward in response. What has followed, somewhat predictably, is a parallel rise in cannabis use disorder—underscoring the clinical reality that cannabis, like any psychoactive substance, carries dependency risk.

Today’s cannabis products are substantially more potent than those available a decade ago. High-THC concentrates often exceed 70%–90% THC. This potency shift is believed to be contributing to rising rates of cannabis use disorder and cannabis-associated psychosis, particularly among adolescents and young adults.

Cocaine & Methamphetamine

Psychostimulants represent a distinct clinical challenge: there are currently no FDA-approved medications for cocaine or methamphetamine use disorder, meaning treatment relies entirely on behavioral interventions—though contingency management has shown considerable promise in clinical trials.

Cocaine

Past-year cocaine use showed a modest decline, dropping from 1.7% to 1.5% of the population (SAMHSA, 2025). Cocaine-involved overdose deaths, however, have been rising when cocaine is combined with fentanyl—sometimes unintentionally on the part of the user. Explore cocaine addiction treatment options in our directory.

Methamphetamine

In contrast to cocaine, past-year methamphetamine use and methamphetamine use disorders have remained essentially unchanged across the most recent survey period (SAMHSA, 2025). Methamphetamine production has shifted overwhelmingly to large-scale manufacturing, producing a product that is cheaper, more pure, and more widely available than ever before. Crystal meth treatment programs must contend with these supply-side realities.

Hallucinogens & Psychedelics

Cultural shifts, legislative experiments in Oregon and Colorado, and a growing body of clinical trial data have all contributed to rising hallucinogen use rates in the United States.

For most adults, hallucinogen use does not meet criteria for a use disorder in the way that opioids, alcohol, or stimulants typically do. However, hallucinogen-induced persistent perception disorder (HPPD) and acute adverse psychiatric events do occur, and clinical resources for these conditions remain limited. Our addiction recovery glossary covers key terminology around these disorders.

It is worth noting that ketamine-assisted therapy is now an established clinical modality for treatment-resistant depression and is being studied in addiction contexts—distinct from recreational ketamine use, which carries its own risks with chronic heavy use.

Nicotine, Tobacco & Youth Vaping

Traditional combustible tobacco use has continued its decades-long decline among young people, but electronic nicotine delivery systems (ENDS)—commonly called vapes or e-cigarettes—have largely absorbed that market shift rather than representing a genuine reduction in nicotine dependence.

This figure demonstrates that vaping has effectively replaced smoking among teens who use nicotine—not supplemented it. Youth nicotine addiction continues to be a significant public health challenge. Nicotine dependence often co-occurs with other addictions and mental health conditions, and is increasingly addressed within residential inpatient settings.

Demographics & Vulnerable Populations

Addiction does not affect all communities equally. Understanding demographic patterns is essential for targeting prevention resources and designing culturally competent treatment programs.

Adolescents & Young Adults

Early onset of substance use is one of the strongest predictors of developing a severe use disorder later in life. The developing adolescent brain is significantly more vulnerable to the effects of substances. See our resources for teen treatment and young adult programs (ages 18–30).

Veterans & Active Military

Veterans face compounding risk factors including PTSD, traumatic brain injury, chronic pain, and the loss of social structure that comes with leaving military service. SAMHSA estimates veterans are at elevated risk for both alcohol use disorder and opioid misuse relative to age-matched civilians. Explore veteran-specific addiction treatment programs.

Women

Research consistently shows that women progress more rapidly from initial substance use to dependence than men—a phenomenon sometimes described as “telescoping.” Women also face distinct barriers including childcare responsibilities, fear of custody loss, and higher rates of co-occurring trauma. Women’s treatment programs address these specific needs.

Older Adults & Seniors

Alcohol misuse among seniors is particularly underdiagnosed. Drug interactions with prescribed medications, social isolation, and bereavement are common precipitating factors. Senior addiction treatment programs offer age-appropriate care.

Professionals

High-functioning substance use disorder is common among healthcare workers, attorneys, and executives. Shame and fear of professional consequences often delay treatment. Programs designed for professionals offer the privacy and structure this population typically requires.

Co-Occurring Mental Health Disorders (Dual Diagnosis)

Addiction rarely exists in isolation. The relationship between substance use disorders and mental health conditions is complex and bidirectional: mental illness can increase vulnerability to substance use, and substance use can trigger or worsen psychiatric conditions.

Common co-occurring conditions include depression, anxiety disorders, PTSD, and bipolar disorder. Treatment is most effective when both conditions are addressed simultaneously. Read our broader resource on mental health disorder and treatment statistics.

Treatment Outcomes & Recovery

Despite the sobering scale of addiction in America, the research on treatment outcomes is clear: professional treatment works, and recovery is achievable. Tens of millions of Americans are in long-term recovery at any given time.

Higher-intensity levels of care—including residential inpatient treatment and partial hospitalization programs (PHP)—are associated with better long-term outcomes for moderate to severe SUDs. Explore our detailed look at rehab, treatment, and detox statistics for outcome data by level of care.

What Makes Treatment Effective

NIDA’s principles of effective treatment identify consistent predictors of positive outcomes: treatment duration of at least 90 days, individualized planning, addressing co-occurring disorders, use of medication where appropriate, and ongoing monitoring. Aftercare planning—including sober living arrangements—significantly reduces relapse rates in the critical first year of recovery.

Relapse, when it occurs, should not be interpreted as treatment failure. NIDA characterizes addiction as a chronic condition with relapse rates similar to those of hypertension and asthma. Returning to treatment following a relapse is both common and clinically appropriate.

Related Resources

For further reading on topics covered in this article, the following resources from Rehab Seekers offer additional clinical depth and practical guidance:

References & Citations

1. Centers for Disease Control and Prevention. (2026). Drug overdose deaths in the United States, 2023–2024. National Center for Health Statistics Data Brief, No. 549. https://www.cdc.gov/nchs/products/databriefs/db549.htm
2. Substance Abuse and Mental Health Services Administration. (2023). Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. HHS Publication No. PEP23-07-01-006. https://www.samhsa.gov/data/
3. Substance Abuse and Mental Health Services Administration. (2025). SAMHSA survey shows four years of mental health, substance use trends. Psychiatric News, 60(9). https://doi.org/10.1176/appi.pn.2025.09.9.34
4. National Institute on Drug Abuse. (2024). Principles of drug addiction treatment: A research-based guide (4th ed.). National Institutes of Health. https://nida.nih.gov/publications/principles-drug-addiction-treatment
5. National Institute on Drug Abuse. (2025). Drug facts: Understanding drug use and addiction. National Institutes of Health. https://nida.nih.gov/publications/drugfacts/understanding-drug-use-addiction
6. American Society of Addiction Medicine. (2023). ASAM clinical practice guideline on alcohol withdrawal management. https://www.asam.org/quality-care/clinical-guidelines
7. National Institute on Alcohol Abuse and Alcoholism. (2024). Alcohol use disorder: A comparison between DSM–IV and DSM–5. National Institutes of Health. https://www.niaaa.nih.gov